ASSESSMENT OF VACCINE/MICROBICIDE COMBINATION EFFICACY IN THE MACAQUE MODEL

猕猴模型中疫苗/杀菌剂组合功效的评估

• 批准号: 8358088
• 负责人: CECILIA C CHENG-MAYER
• 金额: $ 5.78万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8358088
• 关键词: AIDS prevention; Acquired Immunodeficiency Syndrome; Acute; Animals; Development; Funding; Future; Goals; Grant; HIV; HIV vaccine; HIV-1; Heterosexuals; Local Microbicides; Macaca; Modeling; National Center for Research Resources; Nucleocapsid Proteins; Prevention strategy; Primates; Principal Investigator; Prophylactic treatment; Research; Research Infrastructure; Resources; Source; T-Lymphocyte; Testing; United States National Institutes of Health; Vaccinated; Vaccines; Viral; Viral Load result; Viremia; base; cost; inhibitor/antagonist; microbicide; nonhuman primate; pandemic disease; prevent; simian human immunodeficiency virus; transmission process

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Development of an effective vaccine or topical compound to prevent HIV transmission remains a major goal for control of the AIDS pandemic. Using a nonhuman primate model of heterosexual HIV-1 transmission, we tested whether a topical microbicide that reduces viral infectivity can potentiate the efficacy of a partially effective T-cell-based HIV vaccine. A significant delay in simian/human immunodeficiency virus (SHIV) acquisition (Log-rank test; p=0.0416) was seen only in vaccinated macaques that were repeatedly challenged in the presence of a microbicide comprised of an HIV nucleocapsid protein inhibitor. Peak acute viremia was lower (Mann-Whitney test; p=0.0387) and viral burden was also reduced (Mann-Whitney test; p=0.0252) in the combination-treated animals. These findings have implications for future development of HIV prevention strategies employing topical microbicides/pre-exposure prophylaxis (PrEP) and vaccines.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 开发有效的疫苗或外用化合物以防止艾滋病毒传播仍然是控制艾滋病大流行的主要目标。使用非人灵长类动物的异性传播HIV-1模型，我们测试了一种降低病毒传染性的局部杀微生物剂是否可以增强部分有效的基于T细胞的HIV疫苗的效力。猴/人类免疫缺陷病毒(SHIV)获取的显著延迟(对数列检验；p=0.0416)仅在接种了疫苗的猕猴中出现，这些猕猴在含有艾滋病毒核衣壳蛋白抑制剂的杀微生物剂的存在下反复受到挑战。在联合治疗的动物中，急性病毒血症峰值较低(Mann-Whitney检验；p=0.0387)，病毒负荷也减少(Mann-Whitney检验；p=0.0252)。这些发现对采用局部杀微生物剂/暴露前预防(PrEP)和疫苗的艾滋病毒预防战略的未来发展具有重要意义。